Coherus BioSciences Announces New Employment Inducement Grants
REDWOOD CITY, Calif., Dec. 22, 2023 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq:CHRS), today announced that effective December 20, 2023, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 192,000 shares of the common stock of the Company to five newly hired employees with a per share exercise price of $1.94, the closing trading price on the grant date. One Executive Vice President level executive was granted an option to purchase 150,000 shares; and four additional non-officer employees were granted options to purchase an aggregate of 42,000 shares.
Related news for (CHRS)
- Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
- Coherus Divesting UDENYCA Franchise to Intas Pharmaceuticals for up to $558M
- Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP
- Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal
- Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium
